NCT06672536View on ClinicalTrials.gov

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

September 23, 2026

Study Completion Date

January 11, 2027

Conditions
nAMD
Interventions
DRUG

SCT520FF

SCT520FF dose level 1，IVI

DRUG

SCT520FF

SCT520FF dose level 2，IVI

DRUG

SCT520FF

SCT520FF dose level 3，IVI

DRUG

EYLEA 2 MG

EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Eye Hospital, Tianjing

All Listed Sponsors
collaborator

Tianjin Medical University Eye Hospital

OTHER

lead

Sinocelltech Ltd.

INDUSTRY